Clinical Research · Updated May 2026

SUSTAIN Trials: Semaglutide for Type 2 Diabetes

SUSTAIN-1 through SUSTAIN-10. SUSTAIN-6 (NEJM 2016) established 26% MACE reduction. PMID 27633186. Multi-trial pooling on glycemic control and weight outcomes.

Dr. Parmis - Medical Researcher
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Adam Kennah, M.D.
Board-Certified Physician
Last clinically reviewed: April 28, 2026 · This page is informational and does not constitute medical advice.

Summary

SUSTAIN-1 through SUSTAIN-10. SUSTAIN-6 (NEJM 2016) established 26% MACE reduction. PMID 27633186. Multi-trial pooling on glycemic control and weight outcomes.

Source hierarchy

Related clinical pages

Note for patients: Clinical trial data on this site is summarized for general education. Specific dosing decisions, contraindication assessments, and treatment plans must be made with a licensed healthcare provider who has reviewed your full medical history.